Terms: = Leukemia AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Treatment
182 results:
1. Honokiol induces apoptosis and autophagy in dexamethasone-resistant T-acute lymphoblastic leukemia CEM-C1 cells.
Liu Y; Zhang S; Tan Y
Hematology; 2024 Dec; 29(1):2337307. PubMed ID: 38573223
[No Abstract] [Full Text] [Related]
2. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.
Fiskus W; Piel J; Collins M; Hentemann M; Cuglievan B; Mill CP; Birdwell CE; Das K; Davis JA; Hou H; Jain A; Malovannaya A; Kadia TM; Daver N; Sasaki K; Takahashi K; Hammond D; Reville PK; Wang J; Loghavi S; Sen R; Ruan X; Su X; Flores LB; DiNardo CD; Bhalla KN
Blood; 2024 May; 143(20):2059-2072. PubMed ID: 38437498
[TBL] [Abstract] [Full Text] [Related]
3. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
Birdwell CE; Fiskus W; Kadia TM; Mill CP; Sasaki K; Daver N; DiNardo CD; Pemmaraju N; Borthakur G; Davis JA; Das K; Sharma S; Horrigan S; Ruan X; Su X; Khoury JD; Kantarjian H; Bhalla KN
Leukemia; 2024 Mar; 38(3):545-556. PubMed ID: 38086946
[TBL] [Abstract] [Full Text] [Related]
4. Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Sekeres MA; Montesinos P; Novak J; Wang J; Jeyakumar D; Tomlinson B; Mayer J; Jou E; Robak T; Taussig DC; Dombret H; Merchant A; Shaik N; O'Brien T; Roh W; Liu X; Ma W; DiRienzo CG; Chan G; Cortes JE
Leukemia; 2023 Oct; 37(10):2017-2026. PubMed ID: 37604981
[TBL] [Abstract] [Full Text] [Related]
5. Artichoke as a melanoma growth inhibitor.
Mathew AM; Deng Z; Nelson CJ; Mayberry TG; Bai Q; Lequio M; Fajardo E; Xiao H; Wakefield MR; Fang Y
Med Oncol; 2023 Aug; 40(9):262. PubMed ID: 37544953
[TBL] [Abstract] [Full Text] [Related]
6. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A; Alkhateeb H; Gangat N
Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
[TBL] [Abstract] [Full Text] [Related]
7. An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic leukemia.
Patel J; Gao X; Wang H
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108359
[TBL] [Abstract] [Full Text] [Related]
8. Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase.
Zhang C; Zhao X; Wang Z; Gong T; Zhao H; Zhang D; Niu Y; Li X; Zhao X; Li G; Dong X; Zhang L; Liu C; Xu J; Yu B
Invest New Drugs; 2023 Jun; 41(3):438-452. PubMed ID: 37097369
[TBL] [Abstract] [Full Text] [Related]
9. A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.
Wilde L; Porazzi P; Trotta R; De Dominici M; Palmisiano N; Keiffer G; Rancani K; Yingling K; Calabretta B; Kasner M
Leuk Res; 2023 Jun; 129():107075. PubMed ID: 37079999
[TBL] [Abstract] [Full Text] [Related]
10. Childhood cancer survival in the highly vulnerable population of South Texas: A cohort study.
Wu S; Liu Y; Williams M; Aguilar C; Ramirez AG; Mesa R; Tomlinson GE
PLoS One; 2023; 18(4):e0278354. PubMed ID: 37022991
[TBL] [Abstract] [Full Text] [Related]
11. Abemaciclib drives the therapeutic differentiation of acute myeloid leukaemia stem cells.
Xie X; Zhang W; Zhou X; Ye Z; Wang H; Qiu Y; Pan Y; Hu Y; Li L; Chen Z; Yang W; Lu Y; Zou S; Li Y; Bai X
Br J Haematol; 2023 Jun; 201(5):940-953. PubMed ID: 36916190
[TBL] [Abstract] [Full Text] [Related]
12. Glyoxalase 1 inhibitor BBGC suppresses the progression of chronic lymphocytic leukemia and promotes the efficacy of Palbociclib.
Tang J; Zhong J; Yang Z; Su Q; Mo W
Biochem Biophys Res Commun; 2023 Apr; 650():96-102. PubMed ID: 36774689
[TBL] [Abstract] [Full Text] [Related]
13. Accelerated and blast phase myeloproliferative neoplasms.
Saliba AN; Gangat N
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
[TBL] [Abstract] [Full Text] [Related]
14. The International Consensus Classification of acute myeloid leukemia.
Weinberg OK; Porwit A; Orazi A; Hasserjian RP; Foucar K; Duncavage EJ; Arber DA
Virchows Arch; 2023 Jan; 482(1):27-37. PubMed ID: 36264379
[TBL] [Abstract] [Full Text] [Related]
15. A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition.
Soto-Feliciano YM; Sánchez-Rivera FJ; Perner F; Barrows DW; Kastenhuber ER; Ho YJ; Carroll T; Xiong Y; Anand D; Soshnev AA; Gates L; Beytagh MC; Cheon D; Gu S; Liu XS; Krivtsov AV; Meneses M; de Stanchina E; Stone RM; Armstrong SA; Lowe SW; Allis CD
Cancer Discov; 2023 Jan; 13(1):146-169. PubMed ID: 36264143
[TBL] [Abstract] [Full Text] [Related]
16. Galbanic Acid Improves Accumulation and Toxicity of Arsenic Trioxide in MT-2 Cells.
Mahdifar M; Rassouli FB; Iranshahi M; Goudarzi S; Golizadeh M; Rafatpanah H
Anticancer Agents Med Chem; 2023; 23(6):699-708. PubMed ID: 35899960
[TBL] [Abstract] [Full Text] [Related]
17. Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.
Brivio E; Baruchel A; Beishuizen A; Bourquin JP; Brown PA; Cooper T; Gore L; Kolb EA; Locatelli F; Maude SL; Mussai FJ; Vormoor-Bürger B; Vormoor J; von Stackelberg A; Zwaan CM
Eur J Cancer; 2022 Mar; 164():1-17. PubMed ID: 35121370
[TBL] [Abstract] [Full Text] [Related]
18. Combination therapy targeting Erk1/2 and cdk4/6i in relapsed refractory multiple myeloma.
Adamia S; Bhatt S; Wen K; Chyra Z; Fell GG; Tai YT; Pioso MS; Abiatari I; Letai A; Dorfman DM; Hideshima T; Anderson KC
Leukemia; 2022 Apr; 36(4):1088-1101. PubMed ID: 35082402
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods.
Kotrová M; Koopmann J; Trautmann H; Alakel N; Beck J; Nachtkamp K; Steffen B; Raffel S; Viardot A; Wethmar K; Darzentas N; Baldus CD; Gökbuget N; Brüggemann M
Blood Adv; 2022 May; 6(10):3006-3010. PubMed ID: 35026836
[TBL] [Abstract] [Full Text] [Related]
20. Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and cdk4/6 kinase blockade.
Woess K; Macho-Maschler S; Van Ingen Schenau DS; Butler M; Lassnig C; Valcanover D; Poelzl A; Meissl K; Maurer B; Brandstoetter T; Vogl C; Koren A; Kubicek S; Orlova A; Moriggl R; Strobl B; Sexl V; Van Leeuwen FN; Kuiper RP; Mueller M
Haematologica; 2023 Apr; 108(4):993-1005. PubMed ID: 35021603
[TBL] [Abstract] [Full Text] [Related]
[Next]
